Research to watch

[Guest guest]

AAN meeting in San Diego to address research by Don Cleveland that

is groundbreaking. I attended the Annual ALSA meeting a couple of

months ago and heard of this treatment. It is to go to Phase II

trials this year. I believe this would benefit PLS as well as ALS

(an educated guess on my part, but when you hear the details it

stands to reason that it could work for PLS)and I can't wait to see

the results of the phase II trials.

March 31, 2006

AAN Meeting 2006 San Diego: ALS Advances at a Glance

a Friedman, PhD, ALSA Research Department Information

Coordinator

The 2006 annual meeting of the American Academy of Neurology in San

Diego, California on April 2-8 provides ALS researchers from around

the world an opportunity to learn of the most recent advances in the

field that will lead toward more effective therapy. Platform

presentations and poster sessions will highlight important progress

in understanding what goes wrong to produce ALS and how to develop

new strategies for treating the disorder. Sessions throughout the

meeting will focus on developing areas of research with direct

implications for ALS.

Attendees are encouraged to visit The ALS Association booth #1407

during the meeting.

The ALS Association (ALSA) is making available this preview of the

meeting with emphasis on new developments relevant to the disease:

Don Cleveland Ph.D. of the Ludwig Institute, University of

California, San Diego will give a special lecture Thursday, April 6,

9-11am, Exhibit Hall D, titled " From Charcot to Lou Gehrig:

Mechanisms of Motor Neuron Death in ALS. " Details from his team on

antisense and microglia data will be available through a talk and

poster presentations during the meeting. Also on Thursday afternoon

a session will include a report on a Trophos drug found through

screening to be promising for ALS, with Phase II trials expected

this year in the U.S. and Europe, as well as advances in finding

biomarkers for the disease.